REG - Avacta Group PLC - Avacta and Tempus Enter Strategic Collaboration

AvactaAnnouncement

21/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241021:nRSU8592Ia&default-theme=true

RNS Number : 8592I  Avacta Group PLC  21 October 2024

 

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug
Development in Oncology

 

LONDON - Oct. 21, 2024 - Avacta Therapeutics (AIM: AVCT), a life sciences
company developing next generation peptide drug conjugates (PDC) targeting
powerful anti-tumor payloads directly to the tumor, today announces the
initiation of an artificial intelligence (AI)-focused collaboration with
Tempus AI, Inc. (Nasdaq: TEM), a technology company leading the adoption of
artificial intelligence to advance precision medicine and patient care.

 

The strategic collaboration will provide Avacta access to Tempus' multimodal
datasets comprising primary tumor samples and associated clinical data from
over 200,000 patients across a broad range of cancer indications. The
collaboration is designed to leverage these data to characterize the deep
biology of the tumor microenvironment and fibroblast activation protein (FAP)
activity upon which its pre|CISION(®) technology is based.

 

In addition, Avacta has recently expanded its pre|CISION(®) platform with the
addition of two new preclinical programs: AVA6103 and AVA7100. AVA6103 is a
novel pre|CISION(®)-enabled peptide drug conjugate comprising exatecan, a
potent topoisomerase I inhibitor, designed to deliver its powerful anti-tumor
effects directly to the tumor while minimizing exposure to healthy tissues.
AVA7100 is a first-in-class Affimer(®) drug conjugate, aimed at cancers with
varying levels of FAP expression, including low FAP. Together, these programs
reflect the versatility of the pre|CISION(®) platform and its potential to
address a broad range of cancer indications.

 

Avacta plans to leverage these insights to further enhance its pre|CISION(®)
platform reach through the identification of the full addressable patient
populations for its clinical programs. Tempus's analytical support and
computational biology experts will collaborate in the data analysis with the
Avacta team.

 

Christina Coughlin, MD PhD, CEO of Avacta, said, "Our pipeline of
pre|CISION(®) oncology programs will benefit greatly from an extensive
understanding of the tumor microenvironment, FAP biology and both high- and
low-FAP expression across solid tumor settings. The Tempus AI real-world
database and industry-leading AI capabilities will enable us to better assess
the specific patient population most likely to respond to our pre|CISION(®)
therapies, enabling faster, smarter clinical development with the highest
probability of success."

 

Kate Sasser, PhD, Chief Scientific Officer at Tempus AI added, "A powerful use
of AI in drug development is leveraging real-world data to have a deeper
understanding of the patient populations that would benefit from a specific
mechanism of action. Tempus was created to build one of the world's largest
libraries of multimodal data and an operating system to make those data
accessible and useful. This collaboration with Avacta is another example of
our execution of that vision, and we are thrilled to partner with Avacta in
support of their efforts to bring game-changing new therapies to patients in
need."

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc

 Michael Vinegrad, Group Communications Director       https://avacta.com/ (https://avacta.com/)
 Peel Hunt (Nomad and Broker)                          www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden / Patrick Birkholm
 ICR Consilium

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji   avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

About AVA6000

The lead pre|CISION(®) program AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple patients.To register for
news alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

About Avacta Group plc - https://avacta.com/ (https://avacta.com/)

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics. Its
clinical stage oncology biotech division Avacta Therapeutics is harnessing the
proprietary pre|CISION(®) platform technology to develop novel, highly
targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare
professionals and broadening access to diagnostics. To register for news
alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFEIESSELSEFS